Skip to content

About Dr Kate Harrison

Kate’s research experience includes time at the Defence Science and Research Laboratories, investigating universal treatments for emerging diseases, and a PhD at the Roslin Institute, Edinburgh, in the role of novel pro-viral cellular proteins in the growth and replication of vaccinia virus.

Kate then moved to the University of Oxford where she worked in the Neglected Tropical Diseases group at the Jenner Institute, developing vaccines for emerging diseases such as Chikungunya, Zika and Dengue viruses. Her main role was as the lead immunologist for a Phase I clinical trial assessing the safety and immunogenicity of an adenoviral-vectored vaccine for Chikungunya.


Kate teaches Immunology at Level 5, and Clinical Immunology at Level 6, and leads the MSc Infection and Immunity programme.


Kate’s current research involves the development and testing of a vaccine to protect against Chikungunya virus, which has just completed a Phase I clinical trial. She is also currently developing a new project investigating the role of the maternal immune system in breast milk and pregnancy, particularly during viral infection.

Published Work

  • Soares, I.F., López-Camacho, C., Rodrigues-da-Silva, R.N. et al., 2020. Recombinant Plasmodium vivax circumsporozoite surface protein allelic variants: antibody recognition by individuals from three communities in the Brazilian Amazon. Scientific Reports10(1), 14020. doi: 10.1038/s41598-020-70893-3
  • Gupta, N., Harrison, K., et al., 2017. Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chemico-biological interactions267, pp.96-103.
  • Harrison, K., Haga, I., Pechenik Jowers, T., Gillet, D., Schmitt-John, T., Digard, P., Beard, P., 2016. Vaccinia virus uses retromer-independent cellular retrograde transport pathways to facilitate the wrapping of mature virions during viral morphogenesis. Journal of Virology, in press.
  • D'Elia, R.V., Harrison, K., Oyston, P.C., Lukaszewski, R.A. and Clark, G.C., 2013. Targeting the “cytokine storm” for therapeutic benefit. Clin. Vaccine Immunol., 20(3), pp.319-327.

Recent Presentations

  • Harrison, K., et al, 2019. A Phase I study to determine the safety and immunogenicity of a Chikungunya virus vaccine ChAdOx1 Chik in healthy adult volunteers. In: ECCMID, Amsterdam, Netherlands.  Poster Presentation, top rated abstract.
  • Harrison, K., et al, 2018. A Phase I study to determine the safety and immunogenicity of a Chikungunya virus vaccine ChAdOx1 Chik in healthy adult volunteers. In: First International Symposium on Emerging Diseases, NDM Mexico, Puebla. Poster Presentation.
  • Harrison, K., et al., 2016. The role of retrograde transport in Vaccinia virus replication. In: Microbiology Society Annual Conference, Liverpool, UK. Oral presentation.


Associate Fellowship of the Higher Education Academy

Virology PhD, University of Edinburgh, 2018

Microbiology BSc(Hons) with Industrial Experience, University of Manchester, 2013.